Crossmark

Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis

Published Online: 2019-09-03

Published Print: 2019-12

Authors

Bihlet, Asger Reinstrup http://orcid.org/0000-0002-6944-1731
Byrjalsen, Inger

Bay-Jensen, Anne-Christine

Andersen, Jeppe Ragnar

Christiansen, Claus

Riis, Bente Juel

Karsdal, Morten A.
License Information

Text and Data Mining valid from 2019-09-03

Version of Record valid from 2019-09-03
More Information

Article History

Received: 10 January 2019

Accepted: 23 August 2019

First Online: 3 September 2019

Ethics approval and consent to participate

: The trials were approved by all applicable regulatory and ethical bodies before initiation. All participating subjects provided written consent to participate in the trial before any trial procedure was performed.

: Not applicable.

: ARB, IB, ACBJ, CC, BJR, JRA and MAK are full-time employees in Nordic Bioscience, a company engaged in biomarker research and development of treatments for osteoarthritis. The ELISA assays for uCTX-I, uCTX-II and N-MID osteocalcin were developed by Nordic Bioscience but were acquired by Immunodiagnostic Systems UK as Urine Beta Crosslaps®, Urine Cartilaps® and N-MID® Osteocalcin respectively in 2007. ARB, ACBJ, CC, BJR, JRA and MK are shareholders of Nordic Bioscience. BJR and CC are major shareholders and board members of Nordic Bioscience.

Document is current